Format

Send to

Choose Destination
Am J Hypertens. 2015 Mar;28(3):289-99. doi: 10.1093/ajh/hpu197. Epub 2014 Oct 31.

Neuroprotective effects of angiotensin receptor blockers.

Author information

1
Department of Neuroscience, Georgetown University Medical Center, Washington, District of Columbia, USA;
2
Department of Pharmacology and Physiology, Georgetown University Medical Center, Washington, District of Columbia, USA. jms522@georgetown.edu.

Abstract

Angiotensin II receptor blockers (ARBs, collectively called sartans) are widely used compounds therapeutically effective in cardiovascular disorders, renal disease, the metabolic syndrome, and diabetes. It has been more recently recognized that ARBs are neuroprotective and have potential therapeutic use in many brain disorders. ARBs ameliorate inflammatory and apoptotic responses to glutamate, interleukin 1β and bacterial endotoxin in cultured neurons, astrocytes, microglial, and endothelial cerebrovascular cells. When administered systemically, ARBs enter the brain, protecting cerebral blood flow, maintaining blood brain barrier function and decreasing cerebral hemorrhage, excessive brain inflammation and neuronal injury in animal models of stroke, traumatic brain injury, Alzheimer's and Parkinson's disease and other brain conditions. Epidemiological analyses reported that ARBs reduced the progression of Alzheimer's disease, and clinical studies suggested amelioration of cognitive loss following stroke and aging. ARBs are pharmacologically heterogeneous; their effects are not only the result of Ang II type 1(AT1) receptor blockade but also of additional mechanisms selective for only some compounds of the class. These include peroxisome proliferator-activated receptor gamma activation and other still poorly defined mechanisms. However, the complete pharmacological spectrum and therapeutic efficacy of individual ARBs have never been systematically compared, and the neuroprotective efficacy of these compounds has not been rigorously determined in controlled clinical studies. The accumulation of pre-clinical evidence should promote further epidemiological and controlled clinical studies. Repurposing ARBs for the treatment of brain disorders, currently without effective therapy, may be of immediate and major translational value.

KEYWORDS:

Alzheimer’s disease; Parkinson’s disease; angiotensin II; angiotensin receptor blockers; blood pressure; brain inflammation; hypertension; neurodegenerative disorders; neuronal injury; neuroprotection; renin–angiotensin system; sartans; traumatic brain injury.

PMID:
25362113
DOI:
10.1093/ajh/hpu197
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center